FY2017 Earnings Forecast for Spark Therapeutics, Inc. (ONCE) Issued By Jefferies Group

Spark Therapeutics, Inc. (NASDAQ:ONCE) – Investment analysts at Jefferies Group decreased their FY2017 earnings estimates for Spark Therapeutics in a report issued on Tuesday. Jefferies Group analyst M. Yee now forecasts that the biotechnology company will post earnings of ($7.34) per share for the year, down from their previous estimate of ($7.24). Jefferies Group has a “Buy” rating and a $95.00 price target on the stock. Jefferies Group also issued estimates for Spark Therapeutics’ Q4 2017 earnings at ($1.84) EPS, Q3 2018 earnings at ($1.71) EPS and FY2018 earnings at ($6.29) EPS.

Several other equities research analysts have also recently weighed in on the stock. Royal Bank of Canada reduced their price target on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a research report on Wednesday. SunTrust Banks, Inc. set a $101.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th. Barclays PLC boosted their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Cantor Fitzgerald reduced their price target on shares of Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating on the stock in a research report on Friday, October 13th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $101.00 price target (up previously from $92.00) on shares of Spark Therapeutics in a research report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $90.36.

WARNING: “FY2017 Earnings Forecast for Spark Therapeutics, Inc. (ONCE) Issued By Jefferies Group” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/fy2017-earnings-forecast-for-spark-therapeutics-inc-once-issued-by-jefferies-group.html.

Shares of Spark Therapeutics (ONCE) opened at $72.25 on Friday. Spark Therapeutics has a 1 year low of $47.03 and a 1 year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same quarter in the prior year, the firm posted ($1.07) EPS. The company’s revenue for the quarter was up 45.8% on a year-over-year basis.

In other news, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $79.38, for a total transaction of $793,800.00. Following the completion of the sale, the chief financial officer now directly owns 12,500 shares of the company’s stock, valued at $992,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00. Following the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at $18,524,400. The disclosure for this sale can be found here. Insiders have sold 1,080,850 shares of company stock valued at $91,191,774 over the last three months. Insiders own 7.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of Spark Therapeutics by 0.3% during the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock valued at $2,067,000 after purchasing an additional 122 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Spark Therapeutics by 3.2% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 342 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the period. KCG Holdings Inc. boosted its stake in shares of Spark Therapeutics by 9.4% during the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 538 shares during the period. Finally, Teachers Advisors LLC boosted its stake in shares of Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after purchasing an additional 650 shares during the period. 77.30% of the stock is owned by hedge funds and other institutional investors.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply